NEW YORK & TAMPA, Fla.--(EON: Enhanced Online News)--Edgemont
Capital Partners, a leading independent healthcare investment
banking firm, announced that it served as exclusive financial advisor to
Meridien Research Group, a portfolio company of Celerity Partners,
Balance Point Capital and First New England Capital, in its sale to
Avego Healthcare Capital. The transaction closed on April 16, 2018 and
was led by David Blume, Managing Director, Patrick Bradley, Vice
President, Somon Nader, Associate and Dan Smallegan, Analyst. The sale
of Meridien Research is the 21st clinical research site
company transaction closed by Edgemont.

Meridien Research, a leading multi-specialty clinical research site
company operating six sites in Florida, focuses on conducting Phase I-IV
inpatient and outpatient clinical trials across more than 50
indications. The transaction is the third clinical research deal closed
by Edgemont this year, and the seventh in the past nine months. Edgemont
advised Evolution Research Group (ERG) in its acquisition of
Neuropsychiatric Research Group and Wake Research in its sale to M3,
Inc. earlier this year, and in the second half of 2017, advised on ERG’s
acquisitions of Brain Matters Research and Endeavor Clinical Trials, as
well as represented CRISOR and NHCR in their merger to form Velocity
Clinical Research.

“The pace of consolidation is accelerating in the highly fragmented
clinical research site services market. Strategic and financial buyers
are seeking to acquire leading companies in the industry, particularly
those with strong clinical and therapeutic expertise such as Meridien
Research. These acquirers are seeking to capitalize on benefits of scale
for site services, given evolving clinical trials business dynamics and
in order to address the acute challenges of subject recruitment and
increased operational demands placed on sites by sponsors and CROs,”
said Blume.

Founded in 2000, Meridien Research conducts early and late stage
clinical research studies for global and mid-sized pharmaceutical and
biotech sponsors, as well as leading contract research organizations
(CROs), in its six privately-owned clinical trial facilities located in
St. Petersburg, Tampa, Maitland, Spring Hill, Bradenton and Lakeland,
Florida. The Company is a leading research site services company
specializing in a broad range of therapeutic areas, including central
nervous system, mental health, neurology, and metabolic and endocrine
disorders.

About Meridien Research

Meridien Research has been offering medical research to residents of
Central Florida (specifically the Tampa Bay area) since 2000. Meridien
Research’s mission is to provide consistent, high-quality clinical
research in a professional, ethical and timely manner. Meridien has
conducted clinical trials across a wide range of therapeutic areas in
the pharmaceutical, biotechnology and contract research industries.
Meridien Research’s investigators are board certified and specialists in
endocrinology, dermatology, internal medicine, cardiology, central
nervous system disorders and men’s and women’s health. Learn more at www.meridienresearch.net.

Recent Stories

NEW YORK--(EON: Enhanced Online News)--Edgemont Capital Partners, a leading middle market healthcare investment bank with a focus on pharmaceutical services and the top-ranked M&A advisor to cl... more »

NEW YORK & PHOENIX--(EON: Enhanced Online News)--Edgemont Capital Partners, L.P. has acted as exclusive financial advisor to Chandler Radiology Associates (“CRA”) in the sale of the company to Envi... more »